The pharmacokinetics of medroxyprogesterone acetate following two different loading dose schedules in advanced carcinoma of the breast.

por Canney, P. A., Dowsett, M., Priestman, T. J.
Publicado 1988

Ovarian cancer antigen CA125: a prospective clinical assessment of its role as a tumour marker.

por Canney, P. A., Moore, M., Wilkinson, P. M., James, R. D.
Publicado 1984

CA19-9 as a marker for ovarian cancer: alone and in comparison with CA125.

por Canney, P. A., Wilkinson, P. M., James, R. D., Moore, M.
Publicado 1985

Bolus/infusional 5-fluorouracil and folinic acid for metastatic colorectal carcinoma: are suboptimal dosages being used in the UK?

por Jodrell, D. I., Murray, L. S., Reed, N. S., Canney, P. A., Kaye, S. B., Cassidy, J.
Publicado 1994

Phase I study of accelerated FEC with granulocyte colony-stimulating factor (Lenograstim) support.

por Bissett, D., Jodrell, D., Harnett, A. N., Habeshaw, T., Kaye, S. B., Evans, D., Williams, M., Canney, P. A.
Publicado 1995

Evaluation of an inflammation-based prognostic score (GPS) in patients with metastatic breast cancer

por Murri, A M Al, Bartlett, J M S, Canney, P A, Doughty, J C, Wilson, C, McMillan, D C
Publicado 2006

A new immunoassay using monoclonal antibodies HMFG1 and HMFG2 together with an existing marker CA125 for the serological detection and management of epithelial ovarian cancer.

por Dhokia, B., Canney, P. A., Pectasides, D., Munro, A. J., Moore, M., Wilkinson, P. M., Self, C., Epenetos, A. A.
Publicado 1986

Bortezomib/docetaxel combination therapy in patients with anthracycline-pretreated advanced/metastatic breast cancer: a phase I/II dose-escalation study

por Awada, A, Albanell, J, Canney, P A, Dirix, L Y, Gil, T, Cardoso, F, Gascon, P, Piccart, M J, Baselga, J
Publicado 2008

A phase II, multicentre, UK study of vinorelbine in advanced breast cancer.

por Twelves, C. J., Dobbs, N. A., Curnow, A., Coleman, R. E., Stewart, A. L., Tyrrell, C. J., Canney, P., Rubens, R. D.
Publicado 1994

Dihydropyrimidine dehydrogenase pharmacogenetics in patients with colorectal cancer.

por Ridge, S. A., Sludden, J., Wei, X., Sapone, A., Brown, O., Hardy, S., Canney, P., Fernandez-Salguero, P., Gonzalez, F. J., Cassidy, J., McLeod, H. L.
Publicado 1998

Management of cardiac health in trastuzumab-treated patients with breast cancer: updated United Kingdom National Cancer Research Institute recommendations for monitoring

por Jones, A L, Barlow, M, Barrett-Lee, P J, Canney, P A, Gilmour, I M, Robb, S D, Plummer, C J, Wardley, A M, Verrill, M W
Publicado 2009

Bolus/infusional 5-fluorouracil and folinic acid. A report on two prospective, consecutive phase II studies with 5-fluorouracil dose escalation.

por Mackean, M. J., Cassidy, J., Jodrell, D. I., Paul, J., Reed, N. S., Canney, P. A., Yosef, H., Habeshaw, T., Robertson, A. G., McInnes, A., Twelves, C. J.
Publicado 1998

The BIG 2.04 MRC/EORTC SUPREMO Trial: pathology quality assurance of a large phase 3 randomised international clinical trial of postmastectomy radiotherapy in intermediate-risk bre...

por Thomas, J. S., Hanby, A. M., Russell, N., van Tienhoven, G., Riddle, K., Anderson, N., Cameron, D. A., Bartlett, J. M. S., Piper, T., Cunningham, C., Canney, P., Kunkler, I. H.
Publicado en Breast Cancer Res Treat (2017)